Management

Suzanne Bruhn Promedior
Suzanne Bruhn, Ph.D.
President and
Chief Executive Officer
Dr. Bruhn joined Promedior in May 2012 from Shire plc, where she was the Senior Vice President of Strategic Planning and Program Management in the Human Genetic Therapies division and she played a key role in the development of multiple protein therapeutics with annual sales today of over $1 billion. During her 13-year tenure at Shire and Transkaryotic Therapies (acquired by Shire in 2005), she was instrumental in advancing new compounds through clinical development and commercialization, with significant roles driving product strategy, portfolio management, program management, and global regulatory affairs for the rare disease portfolio. Prior to that, she was at Cytotherapeutics, Inc., with an important role developing the encapsulated cell technology platform for ophthalmic delivery. Dr. Bruhn is a member of the Board of Directors of Raptor Pharmaceuticals, a public biotechnology company, and the Crittenton Women's Union, a local non-profit organization. Dr. Bruhn was recognized as a "2013 Woman to Watch" by Mass High Tech. She was a Postdoctoral Fellow in the Department of Human Genetics at Harvard Medical School and earned a Ph.D. in Chemistry from MIT and a B.S. from Iowa State University.
William Hodder
Vice President of
Business Development
Mr. Hodder brings to Promedior more than 25 years of pharmaceutical and biotechnology industry experience. Prior to joining Promedior, Mr. Hodder was founder and CEO of Trenovus, Inc. a start-up biotechnology company focused on developing novel inhibitors of heterotopic ossification. Prior to Trenovus, Mr. Hodder was Vice President, Business Development of FibroGen, Inc., where he was responsible for all licensing and M&A activity. Significantly, Mr. Hodder led FibroGen in the historic out-licensing of HIF prolyl hydroxylase inhibitors for anemia indications to Astellas for the European, South Africa and Middle East territories. Prior to joining FibroGen, he served as Director of Business Development and Marketing at drug delivery company Aradigm and held sales, marketing, and product development positions at Penederm, Ciba Geigy, Bristol-Myers Squibb Company, and Marion Laboratories. Mr. Hodder completed his undergraduate studies at Oakland University with a B.S. in Biology and holds an M.B.A. from the University of Chicago Booth School of Business.
Richard Jack, Ph.D.
Chief Scientific Officer
Dr. Jack has more than 15 years of drug discovery research and development experience in the biotechnology and pharmaceutical industry. Most recently, he led research efforts at Madera Biosciences, a company developing small molecules for the clearance of amyloid β in neurodegenerative diseases. Prior to joining Madera, he was Vice President of Research for Tanabe Research Labs-USA (TRL), the U.S. discovery arm of Mitsubishi-Tanabe Pharma. While there, he and his team advanced multiple small molecule programs to development. Prior to his tenure with TRL, Dr. Jack was a scientific cofounder and Vice President, Biology at Triad Therapeutics, a structure-based drug discovery company that developed a leading kinase inhibitor program that was licensed to Novartis and advanced into human clinical trials. He began his biopharmaceutical career at La Jolla Pharmaceutical, where he developed and advanced preclinical and clinical biologics programs for antibody-mediated diseases. Prior to his work in the biopharmaceutical industry, Dr. Jack spent more than 10 years in the Department of Rheumatology/Immunology at Brigham and Women's Hospital/Harvard Medical School where he was also an NIH-funded faculty member of the graduate programs for both Immunology and Cell and Molecular Biology. His lab focused on mechanisms of autoimmune and inflammatory disease, particularly in the areas of the complement system and leukocyte activation. Dr. Jack is an author of more than 50 scientific papers and three patents. He received an A.B. in Biology from Bates College and a Ph.D. in Immunology from the University of Connecticut Health Center, and he performed his postdoctoral fellowship in Immunoparasitology at ILRAD in Nairobi, Kenya.
Suzanne Bruhn Promedior
Elizabeth G. Trehu, M.D.
Chief Medical Officer
A veteran of the Boston biotech industry and medical community, Dr. Trehu's career has spanned the corporate biopharmaceutical, academic, and private medical practice worlds.  Prior to joining Promedior, Dr. Trehu was most recently vice president of product development and medical affairs at Infinity Pharmaceuticals where, starting in 2010, she was integral in the company's rapid advancement of three clinical programs for product candidates in inflammation and oncology. Prior to Infinity, Dr. Trehu spent four years at Genzyme Corporation, where she began as vice president of oncology global medical affairs and ultimately held the position of vice president and general manager, hematology, with global responsibility for Clolar® (clofarabine), Campath® and Fludara® (fludarabine). From 2002 to 2006, she held positions of increasing responsibility in medical affairs functions at Millennium Pharmaceuticals, principally in support of Velcade® (bortezomib). Dr. Trehu's career prior to industry included laboratory and clinical research in immunotherapeutics as an assistant professor at Tufts University School of Medicine and several years in private practice as a hematologist-oncologist at the Jordan Hospital Club Cancer Center. Dr. Trehu was recognized as a '2012 Woman to Watch' by Mass High Tech.  She holds an M.D. from New York University School of Medicine and an A.B. cum laude from Princeton University.
Suzanne Bruhn Promedior
W. Scott Willett, Ph.D.
Vice President of Biopharmaceutical Development
Dr. Willett has fourteen years of experience in the biopharmaceutical industry in development of protein purification processes for recombinant therapeutics. Prior to joining Promedior in 2007, Dr. Willett served as Director of Process Development at Neose Technologies, leading development and technology transfer for Phase I clinical manufacture of GlycoPEGylation™ processes for improved protein therapeutics. Before joining Neose, Dr. Willett was a Process Development Scientist at Amgen, where he led teams in development of Phase I cGMP purification processes for several proteins, in addition to supporting Amgen's commercial products. Dr. Willett holds a Ph.D. in Pharmaceutical Chemistry from the University of California at San Francisco, and was an NSF Post-doctoral Fellow at the University of Colorado at Boulder. He also earned a B.S. degree in Chemical Engineering from the University of Michigan at Ann Arbor.
Promedior

At Promedior, we are focused on developing novel therapeutics to address the unmet needs of patients with fibrosis. Learn More >